Tampa, FL– Moffitt Cancer Center announces the appointment of Dr. Timothy Yeatman as the executive vice president and founding chief scientific officer (CSO) for M2Gen. In his new role, Yeatman will lead M2Gen in its scientific medical initiatives and support its commercial endeavors to bring a personalized medicine approach to cancer patients by finding new ways to speed the development and delivery of pipeline therapies. He will help develop the M2Gen infrastructure to interface with the Moffitt Total Cancer Care™ initiative and use the biorepository to find the right drug trials for the right patients. Yeatman will report to James D. Utterback, CEO of M2Gen.
Total Cancer Care™ is Moffitt’s comprehensive approach to cancer care – designed to enable researchers and caregivers to identify and meet all the needs of a patient and his or her family during the patient’s lifetime and for future generations. The approach addresses cancer as a public health issue and takes a holistic approach by encompassing all aspects of the disease, including preventative measures such as the study of genetic predispositions, the impact of health lifestyles and integrative medicine.
“M2Gen is poised for tremendous growth and having Dr. Yeatman on our management team will position M2Gen to leverage the marketplace opportunities that lie ahead,” Utterback said.
“Dr. Yeatman has contributed greatly to Moffitt’s success through the years,” said William S. Dalton, Ph.D., M.D., CEO and center director of Moffitt. “I look forward to continuing to collaborate with him to improve the lives of cancer patients through Total Cancer Care™.”
Yeatman will also continue to serve as professor of surgery and senior member of Moffitt Medical Group and the Moffitt Research Institute, as well as head of the Hepatobiliary Division of the Gastrointestinal Oncology Program at Moffitt.
During the past 18 years, Yeatman has held numerous positions at Moffitt including GI Oncology Program leader, associate center director for Clinical Investigations and executive vice president for Translational Research and director of Total Cancer Care™. He received his undergraduate degree from Duke University, his medical degree from Emory University, and completed his surgical residency at the University of Florida and surgical oncology fellowship at MD Anderson Cancer Center. Yeatman has published more than 150 articles in the top peer-reviewed journals in his field including Science, Nature Genetics, Nature Medicine, Nature Reviews Cancer, as well as the Journal of the National Cancer Institute, Journal of Clinical Oncology, Oncogene, Proceedings of the National Academy of Sciences and Cancer Research.
About Moffitt Cancer Center
Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.